Health Care Activity
Pfizer Unveils PfizerForAll, a Direct-to-Consumer Platform for Migraine, Flu, and COVID-19 Products
PfizerForAll, Direct-to-Consumer, Migraine, Flu, COVID-19, Telehealth, Prescription Services, Vaccination Scheduling, Savings Programs
Pfizer Launches PfizerForAll: A Digital Platform to Simplify Healthcare Access
PfizerForAll, digital healthcare platform, telehealth, COVID-19, flu, migraines, healthcare access, patient support services
Qventus Launches AI Operational Assistants to Boost Healthcare Productivity
Qventus, AI Operational Assistants, Healthcare Productivity, Administrative Tasks, Patient Care
Walgreens’ Three-Year Revival Plan: Strategic Store Closures and Enhanced Healthcare Services
Walgreens, retail pharmacy, store closures, healthcare services, profitability, strategic review
US Lawmakers Demand FDA Probe into Clinical Trials Linked to China’s Military
FDA investigation, clinical trials, China’s military, US lawmakers, bipartisan scrutiny
Avantor Divests Clinical Services Unit to Audax Private Equity for $650 Million
Avantor, Clinical Services, Audax Private Equity, Divestiture, Laboratory Products, Bioscience Production
FDA Clears BioNTech-MediLink ADC Trial to Resume with Reduced Doses
BioNTech, MediLink, ADC trial, FDA approval, lower doses, cancer treatment, HER3, patient safety
Merck Acquires Curon’s Bispecific Antibody in $1.3B Deal; Legend Biotech Evaluates Options Amid Probes; Amgen’s FDA Filing Reveals Missing Adverse Events
Merck, Curon Biopharmaceutical , Bispecific antibody, Legend Biotech, Amgen, FDA filing, Adverse events, China investigations, CAR-T therapy, Carvykti
Biden Administration Announces Historic Lower Drug Prices for Medicare Beneficiaries
Biden Administration, Medicare, Drug Prices, Inflation Reduction Act, Prescription Drug Costs
Landmark Medicare Negotiations Set Prices for 10 Key Drugs, Projecting Billions in Savings
Medicare, drug prices, Biden administration, pharmaceutical companies, Inflation Reduction Act, prescription drugs, seniors, healthcare costs